Trends in Prostate Cancer Epidemiology in Slovakia – an International Comparison
Authors:
M. Ondrušová 1,2; D. Ondruš 3
Authors‘ workplace:
Pharm-In, spol. s r. o., Bratislava
1; Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety, Bratislava
2; I. onkologická klinika LF UK a Onkologického ústavu sv. Alžbety, Bratislava
3
Published in:
Klin Onkol 2017; 30(2): 115-120
Category:
Original Articles
doi:
https://doi.org/10.14735/amko2017115
Overview
Introduction:
According to worldwide estimates, Slovakia is classed as a country with a medium-high incidence of prostate cancer. Current predictions indicate that in the near future prostate cancer will become the most frequent cancer among males in Slovakia.
Aims:
The aims of the study presented in this paper were to analyse trends in the incidence and mortality of prostate cancer in Slovakia and compare these trends with those in other countries and regions of the world, predict epidemiological indicators of prostate cancer in Slovakia, and provide relevant and updated data for the purposes of further analyses and evaluation of the impacts of interventions.
Material and Methods:
National data were analysed for the period 1968–2009. Trends in prostate cancer incidence and mortality were extracted using the joinpoint regression model and are presented with correspoding 95% CI and p values. Predictions of incidence and prevalence were calculated for the years 2014 and 2015, resp.
Results:
A significant increase in standardized incidence was observed in Slovakia (from 14.5/100,000 in 1980 to 49.0/100,000 in 2009), representing as much as a 6.7% annual percentage change in recent years. The mortality values showed a slower rate of increase, from 9.4/100,000 in 1980 to 13.3/100,000 in 2009, while national mortality of prostate cancer decreased in recent years. These facts have made prostate cancer the most prevalent malignant tumor in males in Slovakia.
Conclusion:
Unlike in other countries, in Slovakia, no peak in prostate cancer incidence with a subsequent drop is observed. Mortality values reveal a favorable trend in the current national data.
Key words:
prostate cancer – incidence – mortality – prevalence – clinical stages
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
14. 12. 2016
Accepted:
25. 1. 2017
Sources
1. Signorello LB, Adami HO. Prostate cancer, chapter 18. In: Adami HO, Hunter D, Trichopoulos D (eds). Textbook of cancer epidemiology. New York: Oxford University Press Inc 2002: 400–428.
2. Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am 2003; 30 (2): 209–217.
3. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, IARC, 2013; [cited 2016 Oct 10]. Available from: http: //globocan.ia rc.fr.
4. Gatta G, Zigon G, Buemi A et al. Prostate cancer treatment in Europe at the end of 1990s. Acta Oncol 2009; 48 (6): 867–873. doi: 10.1080/02841860902719 174.
5. Ondrušová M, Pleško I, Safaei-Diba CH et al. Komplexná analýza výskytu a úmrtnosti na zhubné nádory v Slovenskej republike (online). Bratislava: NOR SR, NCZI 2007. Dostupné z: www.nor-sk.org.
6. Ondrušová M, Pleško I, Safaei-Diba CH et al. Incidencia zhubných nádorov v Slovenskej republike 2003. 2. vyd. Bratislava: NOR SR, NCZI 2007: 229.
7. Safaei-Diba CH, Pleško I, Frindtová V et al. Incidencia zhubných nádorov v Slovenskej republike 2004. Bratislava: NOR SR, NCZI 2008: 168.
8. Safaei-Diba CH, Pleško I, Obšitníková A et al. Incidencia zhubných nádorov v Slovenskej republike 2005. Bratislava: NCZI 2009: 173.
9. Safaei-Diba CH, Pleško I, Hlava P (eds). Incidencia zhubných nádorov v Slovenskej republike 2006. Bratislava: NCZI 2010: 177.
10. Safaei-Diba CH, Pleško I, Hlava P (eds). Incidencia zhubných nádorov v Slovenskej republike 2007. Bratislava: NCZI 2012: 135.
11. Safaei-Diba CH, Pleško I (eds). Incidencia zhubných nádorov v SR 2008. Bratislava: NCZI 2014: 175.
12. Safaei-Diba CH (ed.). Incidencia zhubných nádorov v SR 2009. Bratislava: NOR SR, NCZI 2015: 191.
13. Kolektiv autorov. Úmrtnostné tabuľky SR. Štatistický úrad SR (online). Dostupné na: http: //slovak.statistics.sk/wps/portal/ext/themes/demography/population/indicators/: Obyvateľstvo a migrácia, príčiny smrti: nádory 2015.
14. Join point regression program, Version 4.2.0.1. May 2015; Statistical Research and Application Branch, National Cancer Institute, Bethesda.
15. Kim HJ, Fay MP, Feuer EJ et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19 (3): 335–351.
16. Clegg LX, Hankey BF, Tiwari R et al. Estimating average annual percent change in trend analysis. Stat Med 2009; 28 (29): 3670–3682.
17. Ondrušová M, Ondruš D. Karcinóm prostaty – vývoj incidencie a mortality na Slovensku v porovnaní so zahraničím. Onkológia (Bratisl.) 2013; 8 (1): 29–31.
18. Ondrušová M, Kliment J, Pšenková M. Vybrané ukazovatele epidemiológie karcinómu prostaty na Slovensku. Onkológia (Bratisl.) 2015; 10 (4): 226–229.
19. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13): 1310–1319. doi: 10.1056/NEJMoa0810696.
20. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Verze 7.0 [2007]. Masarykova univerzita 2005, [citováno 13. prosince 2016]. Dostupný z: http: //www.svod.cz.
21. Kaušitz J. Možnosti využitia rádioimunoanalýzy nádorových markerov pri diagnostike karcinómov testes a prostaty. Bratisl Lek Listy 1988; 89 (10): 715–724.
22. Wong MC, Goggins WB, Wang HH et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol 2016; 70 (5): 862–874. doi: 10.1016/j.eururo.2016.05.043.
23. Levi F, Lucchini F, Negri E et al. Leveling on prostate cancer mortality in Western Europe. Prostate 2004; 60 (1): 46–52.
24. Jemal A, Center MM, DeSantis C et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19 (8): 1893–1907. doi: 10.1158/1055-9965.EPI-10-0437.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2017 Issue 2
Most read in this issue
- Chemotherapy-related Cognitive Impairment in Patients with Hodgkin Lymphoma – Pathophysiology and Risk Factors
- Coffee in Cancer Chemoprevention
- Trends in Prostate Cancer Epidemiology in Slovakia – an International Comparison
- Stereotactic Body Radiotherapy of Prostate Cancer – Effectiveness and Toxicity